Fabrication, characterization and in vivo studies of biodegradable gamma sterilized injectable microparticles for contraceptionVavia

Pharmaceutical Development and Technology

Volumn 14, Issue 3, 2009, Pages 278-289

  Puthli, Shivanand P ^a   Vavia, Pradeep R ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Bovine serum albumin; Contraceptive; Gelatin; Levonorgestrel; Microparticle

Indexed keywords

BOVINE SERUM ALBUMIN; GELATIN; LEVONORGESTREL; POLYMER; SOLVENT; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION; MICROSPHERE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTRACEPTION; CONTROLLED STUDY; CROSS LINKING; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; EMULSION; ENCAPSULATION; FEMALE; GAMMA IRRADIATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INJECTION; KINETICS; MALE; MOISTURE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RABBIT; RADIOIMMUNOASSAY; SCANNING ELECTRON MICROSCOPY; TIME; X RAY DIFFRACTION; ANIMAL; BOVINAE; CHEMISTRY; DELAYED RELEASE FORMULATION; GAMMA RADIATION; INSTRUMENT STERILIZATION;

ANIMALS; CATTLE; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; GAMMA RAYS; GELATIN; INJECTIONS; LEVONORGESTREL; MICROSPHERES; RABBITS; SERUM ALBUMIN, BOVINE; STERILIZATION;

EID: 70350645057     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802585260     Document Type: Article

References (33)

1. Reis CP, Neufeld RJ, Vilela S, Ribeiro A.J, Veiga F. Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles. Microencapsul. 2006;23:245-257.
2. Shi Y, Li LC.Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv. 2005;2:1039-1058.
3. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microparticle preparation process technology. J Control Release. 2005;102:313-332.
4. Okada H, Toguchi H. Biodegradable microparticles in drug delivery. Crit Rev Therap Drug Carrier Syst. 1995;2:1-99.
5. Drieu K, Devissaguet JP, Duboistesselin R, Dray F, Ezan E. Pharmacokinetics of D-Trp6 LHRH in man: sustained release polymer microparticle study (I.M. route). Prog Clin Biol Res. 1987;243A:435-437.
6. Dhanaraju MD, Rajkannan R, Selvaraj D, Jayakumar R, Vamsadhara C. Biodegradation and biocompatibility of contraceptive- steroid-loaded poly (DL-lactide-co-glycolide) injectable microparticles: in vitro and in vivo study. Contraception. 2006;74:148-156.
7. Dhanaraju MD, Gopinath D, Ahmed MR, Jayakumar R, Vamsadhara CJ. Characterization of polymeric poly(epsiloncaprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. Biomed Mater Res. 2006;76:63-72.
8. Urata T, Arimori K, Nakano M. Modification of release rates of cyclosporin A from polyl(L-lactic acid) microparticles by fatty acid esters and in vivo evaluation of the microparticles. J Control Release. 1999;58:133-141.
9. Viswanathan NB, Thomas PA, Pandit JK, Kulkarni MG, Mashelkar RA. Preparation of non-porous microparticles with high entrapment efficiency of proteins by a (water-in-oil)-in-oil emulsion technique. J Control Release. 1999;58:9-20.
10. Sah HK, Chien YW.Evaluation of a microreservoir-type biodegradable microcapsule for controlled release of proteins. Drug Dev Ind Pharm. 1993;19:1243-1263.
11. Heya T, Okada H, Ogawa Y, Toguchi H. Factors influencing the profiles of TRH release from copoly(d,l-lactic/glycolic acid) microparticles. Int J Pharm. 1991;72:199-205.
12. Chattaraj SC, Rathinavelu A, Das SK. Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. J Control Release. 1999;58:223-232.
13. Yoshikawa Y, Komuta Y, Nishihara T, Itoh Y, Yoshikawa H, Takada K. Preparation and evaluation of once-a-day injectable microparticles of interferon alpha in rats. J Drug Target. 1999;6:449-461.
14. Guo R, Lu B. Study on compound levonorgestrel microparticles. Hua Xi Yi Ke Da Xue Xue Bao. 1993;24:376-380.
15. Chen Y, Willmott N, Anderson J, Florence AT. Comparison of albumin and casein microparticles as a carrier for doxorubicin. J Pharm Pharmacol. 1987;39:978-985.
16. Jones C, Burton MA, Gray BN. Albumin microparticles as vehicles for the sustained and controlled release of doxorubicin. J Pharm Pharmacol. 1989;41:813-816.
17. Orienti I, Zecchi V. Progesterone-loaded albumin microparticles. J Control Release. 1993;27:1-7.
18. Egbaria K, Friedman M. Sustained release albumin microparticles containing antibacterial drugs: effects of preparative conditions on kinetics of drug release. J Control Release. 1990;14:79-94.
19. Luftenstelner CP, Schwendenwein I, Paul B, Eichler HG, Viernstein H. Evaluation of mitoxantrone-loaded albumin microparticles following intraperitoneal administration to rats. J Control Release. 1999;57:35-44.
20. Lovgren K, Lundberg P.Determination of sphericity of pellets prepared by extrusion/spheronization and the impact of some process parameters. Drug Dev Ind Pharm. 1989;15:2375-2392.
21. Farmacopea Ufficiale Italiana, IX. Vol.1; 1985, pp. 744.
22. United States Pharmacopoeia, Microbiological tests: Sterility Tests, USP 29-NF 24, The United States Pharmacopoeial Convention, Inc., Rockville; 2006.
23. European Pharmacopoeia, Test for abnormal toxicity, Ph. Eur. method 2.6.9, Council of Europe; 2005, Appendix XIVE.
24. European Pharmacopoeia, Test for pyrogens, Ph. Eur. method 2.6.8, Council of Europe; 2005, Appendix XIVD.
25. Higuchi T. Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
26. Doshi CC, Bhalla HL. In vitro release studies of levonorgestrel loaded biodegradable microspheres. Ind J Pharm Sci. 1999;61:39-43.
27. Ranga Rao KV, Padmalatha DK, Buri PK. Cellulose matrices for zero-order release of soluble drugs. Drug Dev Ind Pharm. 1988;14:2299-2320.
28. Roy S, Stanczyk FZ, Mishell DR, Lumkin M, Gentzschein E. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods. Contraception. 1980;21:595-615.
29. Moore DE, Roy S, Stanczyk FZ, Mishell DR. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception. Contraception. 1978;17:315-328.
30. Ory SJ, Hammond CB, Yancy SG, Hendren RW, Pitt CG. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels. Am J Obstet Gynecol. 1983;145:600-605.
31. Sivin I, Lähteenmäki P, Ranta S, Darney P, Klaisle C, Wan L, Mishell DR, Lacarra M, Viegas OA, Bilhareus P, Koetsawang S, Piya-Anant M, Diaz S, Pavez M, Alvarez F, Brache V, LaGuardia K, Nash H, Stern J. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception. 1997;55:81-85. (Pubitemid 27114530)
32. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M, Simionescu L ,Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45:67-71.
33. Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. J Pharm Sci. 2000;89:1123-1133.